Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 075 IN DEXTROSE 10 AND SODIUM CHLORIDE 0 45 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 075 IN DEXTROSE 10 AND SODIUM CHLORIDE 0 45 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Potassium chloride dissociates to provide potassium ions, which are essential for maintenance of intracellular tonicity, nerve impulse transmission, contraction of cardiac, skeletal, and smooth muscle, and normal renal function. Dextrose provides caloric support and is metabolized via glycolysis and the Krebs cycle. Sodium chloride provides sodium and chloride ions to maintain extracellular fluid volume and osmolality.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
Intravenous infusion. Dose is determined by electrolyte requirements and fluid status. Typical maintenance: 1-2 mEq/kg/day potassium chloride, 100-200 mL/kg/day dextrose 10% (providing 10-20 g/kg/day dextrose), and sodium chloride 0.45% (providing 0.45 g/kg/day sodium chloride). Administer at a rate not exceeding 10 mEq/h potassium chloride via peripheral line; central line may allow up to 20 mEq/h with continuous cardiac monitoring.
None Documented
None Documented
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
Potassium: not classically defined due to rapid cellular redistribution; terminal half-life for administered K+ is approximately 1-1.5 hours in healthy individuals. Dextrose: distribution half-life ~5-10 min; elimination depends on utilization and renal function. Sodium chloride: no defined half-life; excreted based on body needs.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Potassium: primarily renal excretion (>90%) via distal tubular secretion; negligible biliary or fecal. Dextrose: metabolized to CO2 and water; renal excretion of unchanged glucose negligible (glycosuria if threshold exceeded). Sodium chloride: renal excretion (Na+ and Cl-) with homeostasis; extrarenal losses minimal under normal conditions.
Category C
Category A/B
Electrolyte
Electrolyte